Chargement en cours...
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
PURPOSE: Although dose-intensive strategies or high-dose therapy induction followed by autologous stem-cell transplantation have improved the outcome for patients with mantle-cell lymphoma (MCL), most eventually relapse and subsequently respond poorly to additional therapy. Bortezomib (in the United...
Enregistré dans:
| Publié dans: | J Clin Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Clinical Oncology
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4879693/ https://ncbi.nlm.nih.gov/pubmed/24002500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.49.2835 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|